Board summary
Key figures
31,418
Registered population
60.3% aged 18–64
19.6%
Aged 65+
ICB 20.0% · England 17.9%
6.4%
Ethnic minority (non-White)
4.3% Asian · England 9.6%
40.8%
In IMD quintile 1
ICB 30.6% · England 21.0%
~13,060
Core20 residents (est.)
Resident basis; registered basis ~12,438 · see page 3
5,729
Hypertension register
+6.45% in 3 yrs · England +5.60%
325
SMI register
39.5% of Rossendale's
1,000
COPD register
Reviews +8.34% in 3 yrs
Forecast to 2030
6,564
Hypertension patients, 2030
+835 on today
66.0%
QRISK ≥20% on statins, 2030
+1.06pp over 3 yrs
5.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Dementia register fell while national prevalence grew.
Recorded dementia prevalence fell 13.0% over 2023 to 2025 (England +6.0%) to 227 patients, which may reflect unverified coding or care-home case-finding gaps.
Heart failure annual reviews trail all comparators.
Annual heart failure functional reviews reached 70.5% of the 308-patient register (Rossendale 75.1%, ICB 78.9%, England 78.5%), which could reflect unverified recall gaps.
Non-frail diabetes glycaemic control exceeds national average.
HbA1c control in non-frail diabetes reached 61.6% (Rossendale 58.4%, ICB 56.2%, England 57.4%) after +18.4% three-year growth (England +4.4%).
Population, age and ethnicity
Older adults make up 19.6% of patients, while ethnic minorities represent 6.4%
Across 31,418 registered patients, ranging from 6,739 at Whitworth Medical Centre to 15,409 at Irwell Medical Practice, adults aged 65+ make up 19.6% (6,153 patients), compared with 17.6% in Rossendale, 20.0% in the ICB and 17.9% in England. Projected list growth to 2030 is 0.7% (Rossendale 1.2%, ICB 1.7%, England 2.3%; unverified method). Census resident estimates show 93.6% White ethnicity (Rossendale 92.4%, ICB 87.8%, England 81.1%), leaving a 6.4% ethnic minority share, and 4.3% Asian (Rossendale 5.5%, ICB 9.4%, England 9.6%). These resident bases do not represent registered patient ethnicity.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Rossendale local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rossendale LA) | 1,799 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rossendale LA) | 839 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rossendale LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 40.8% across the PCN and varies sharply between practices
Across the PCN, 40.8% of registered patients live in Core20 areas, above Rossendale (29.3%), the ICB (30.6%) and England (21.0%). Whitworth Medical Centre has a 0.0% Core20 share. Waterfoot Medical Practice has a 37.8% Core20 share (3,505 estimated patients). Irwell Medical Practice has a 58.0% Core20 share (8,933 estimated patients), creating a 58.0 pp practice range. Average IMD decile is 3.4. Weighted practice shares total 39.6%. Estimated Core20 patients are concentrated in Irwell Medical Practice and Waterfoot Medical Practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
325
SMI register
1.03% recorded prevalence
220
Learning disability register
0.70% recorded prevalence
19
Care homes, 463 beds
In the PCN catchment
9.3%
Provide unpaid care
Rossendale, Census 2021
Recorded registers comprise 220 patients with learning disabilities (0.7% vs 0.6% in England) and 325 with severe mental illness (1.0%, matching England), alongside 463 care-home beds across 19 catchment sites. Borough unpaid carers (9.3%) and rough sleeping (0 in 2025) remain local-authority metrics.
Severe mental illness: physical health checks
On the 325-patient SMI register (1.0% prevalence), annual physical check completion trails England: blood pressure checks reached 78.7% (England 83.4%) and BMI recording reached 76.0% (England 82.1%). Dedicated recall could support physical health monitoring across both checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,729
Hypertension register
+6.45%
Register growth, 3 yrs
Rossendale +7.87% · England +5.60%
+2.66pp
BP control, under 80
≤140/90 · +1.48pp aged 80+
+835
More patients by 2030
Forecast 6,564 (20.56%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.1% (5,729 patients), above Rossendale (16.9%), the ICB (17.2%) and England (15.2%). Blood pressure treated to target reaches 71.1% (England 70.3%). However, recent blood pressure readings stand at 88.1% (England 90.0%), and under-80 control is 67.7% (England 67.8%), ranging from 58.5% at Whitworth Medical Centre and 63.8% at Irwell Medical Practice to 82.6% at Waterfoot Medical Practice. An unverified model projects 6,564 patients by 2030 (an increase of 835). Practice-level variation in blood pressure control may reflect differences in review pathways, suggesting scope to review recall protocols at lower-achieving practices.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% patients sits at 63.8% (England 63.6%), but three-year growth (+1.7%) lagged England (+6.2%). Prescribing of lipid-regulating drugs in adults (2,607 items per 1,000) also trails England (4,100). Slower growth in therapy initiation may reflect differences in cardiovascular risk review routines.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 65,424 | £1.50 | £1.64 | £1.86 | £98,136 |
| Cardiovascular (all), 2025 | 87,009 | £3.70 | £3.38 | £3.33 | £321,933 |
In 2026, the PCN prescribed 65,424 lipid-regulating drug items at £1.50 per item (Rossendale £1.55, ICB £1.64, England £1.86), totaling £98,136, which is £23,553 less than at England's unit cost. Lower unit cost than England illustrates lower expenditure per item, though this indicator does not evaluate prescribing efficiency or clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.60%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.2% (1,000 patients), above Rossendale (2.6%) and England (1.9%), with 82.5% receiving an annual review (England 76.4%). Asthma prevalence is 9.3% (2,769 patients; England 6.6%), and 1,664 asthma management items were prescribed per 1000 5-19 Population (England 1,488). While asthma reviews reached 68.0% (England 65.7%), an estimated 887 patients—about 890—remain without a recorded annual review.
Cancer register and children's immunisation
The cancer register records 1,306 patients (4.1% prevalence; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 24 months reached 100.0% (denominator 56) and age-5 MMR1 reached 96.6% (denominator 87). However, age-5 coverage falls to 93.1% for MMR2 (1.9 pp below the 95.0% target) and 88.5% for 4-in-1 (6.5 pp below the target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage (4,642 of 8,863 staged cases; 74.6% known-stage share) in NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2, trailing England (55.3%) and below the 75.0% national ambition by 22.6 pp. The ICB early-stage share fell 1.2 pp from 2013 to 2022, requiring about 2,010 extra early-stage cases annually across the ICB. In the PCN, cervical screening reached 74.0% (England 66.8%) but fell 1.5% over 2023 to 2025 (England -1.0%). Maintaining proactive primary care screening recall is necessary to support early presentation before patients enter secondary diagnostic pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For East Lancashire Hospitals NHS Trust, July 2026 provisional data shows 73.2% of patients met the cancer 62-day treatment standard, below the 85.0% standard by 11.8 pp, while exceeding England (71.2%) and trailing Northern Care Alliance NHS Foundation Trust (78.6%) and the ICB (73.6%). The trust achieved the 28-day faster diagnosis standard at 81.5% (standard 75.0%; England 79.3%). Across all diagnostic tests, 3.2% waited 6+ weeks (England 23.1%), though cystoscopy waits reached 32.7% (England 24.4%). Robust primary care safety-netting is crucial while secondary treatment pathways experience 62-day delays.
| Pathways within standard (%) | East Lancashire | Northern Care Alliance | Bolton | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 75.20 | 80.48 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 94.54 | 96.50 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 78.65 | 69.66 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Northern Care Alliance | Bolton | England |
|---|---|---|---|---|
| MRI | 0.43 | 5.09 | 2.05 | 21.40 |
| CT | 0.15 | 4.10 | 19.40 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 3.48 | 28.48 |
| Colonoscopy | 0.95 | 40.04 | 1.33 | 30.83 |
| Gastroscopy | 1.16 | 36.48 | 2.06 | 29.02 |
| All 15 DM01 tests | 3.25 | 15.71 | 15.78 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 provisional experimental data, Lancashire residents recorded 293,090 community care activities, within 533,345 across NHS Lancashire and South Cumbria Integrated Care Board. Contacts with adults aged 65+ accounted for 56.9% of borough residents' community contacts (72,000 of 126,445). Linking community nursing into primary care palliative and cancer reviews can improve home-based support.
Practice variation and patient experience
Phone ease varies by 25.7 pp across practices despite uniform overall good experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Waterfoot Medical | 100 | 37.8 | 69.4% | 70.3% | 81.2% |
| Irwell Medical | 105 | 58.0 | 70.2% | 67.1% | 79.6% |
| Whitworth | 109 | 0.0 | 44.5% | 75.6% | 79.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia registers fell 13.0% and heart failure reviews lagged England over three years
Over 2023 to 2025, Rossendale East PCN trailed England on 10 of 25 trajectories. Relative change lagged most on the dementia register, which fell 13.0% (England +6.0%), and heart failure reviews (+0.2% vs England +8.7%). Smoking cessation offers fell 1.4 pp (England +0.1 pp). Conversely, relative gains exceeded England in non-frail diabetes HbA1c control (+18.4% vs +4.4%), secondary-prevention statins in diabetes (+6.0% vs +1.0%), and learning disability register growth (+14.7% vs +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
QRISK statin treatment
Stroke register
Smoking support (SMI)
Diabetes HbA1c control
COPD reviews
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rossendale | Asset | PCN | Rossendale |
|---|---|---|---|---|---|
| Care homes (catchment) | 19 (463 beds) | n/a | Schools (catchment) | 43 | n/a |
| Children's centres | 4 | 5 | Places of worship | 32 | 44 |
| Libraries | 3 | 4 | Homelessness support (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 16 | 25 | Primary academies | 2 | 2 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Dementia register and care-home review
Dementia prevalence is 0.7% (227 patients) vs 0.8% in Rossendale and England (19 to 26 benchmark patient gap), after falling 13.0% over 2023 to 2025 (England +6.0%). For discussion: audit clinical records across the 463 catchment care-home beds for unrecorded diagnoses and review memory-assessment referral pathways. Moderate effort to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Option 2
Heart failure review and register audit
Annual heart failure functional reviews reached 70.5% vs 75.1% in Rossendale and 78.5% in England (below England by 8.1 pp). The 308-patient register (1.0%) shows a -17 to +37 benchmark range. Moderate effort to run.
Option 3
Structured annual asthma review recall
Asthma prevalence is 9.3% (2,769 patients vs 6.6% in England). Although annual reviews reached 68.0% (England 65.7%), an estimated 887 patients (about 890) had no recorded review. For discussion: combine annual asthma review invitations with repeat inhaler prescribing reviews and offer flexible or remote appointment slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 health outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Dementia register and care-home review (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Option 2 · Heart failure review and register audit (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | — | PCN |
| Option 3 · Structured annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
